Extended Data Fig. 10: Diagram illustrating PCSK9-mediated degradation of MHC I in the lysosome.
From: Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Left, in the presence of PCSK9, MHC I is transported into lysosomes and degraded. Right, in the absence of PCSK9 (through genetic deletion or antibody-mediated neutralization), MHC I levels on the surface remain high and can thus present tumour-specific peptide antigens more efficiently to T cells. Illustration by S. Coffman.
